Zhengbin (Bing) Yao, Ph.D

Zhengbin (Bing) Yao, Ph.D

Chief Executive Officer and PresidentatArriVent BioPharma· In proxies 2023–2025

Pay in FY2025+290% from the year before · ArriVent BioPharma stock -24.5% the same year

Zhengbin (Bing) Yao, Ph.D was paid $9.4M in FY2025 (Dec), up 290%. ArriVent BioPharma stock fell 24.5% that year.

Pay$100 in the stock at the end of FY24 → $76
Pay is from the Summary Compensation Table of each ArriVent BioPharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. ArriVent BioPharmaPublic company · 3 yr
    • Chief Executive Officer and President2023 – Present · 3 yrStock in role -21%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?